Morepen Laboratories, 500288, MOREPENLAB Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

3,081.14
24.46
2

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

3,059.26
N/A
2.71

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

15.48
14.66
3.00

EBITDA CAGR (%)

10 Years
5 Years
3 Years

12.64
18.28
3.02

PAT CAGR (%)

10 Years
5 Years
3 Years

46.30
23.42
-1.84

P:E (Median)

8 Years
5 Years
3 Years

29.36
27.40
31.41

P:BV (Average)

8 Years
5 Years
3 Years

3.82
3.51
2.75

EV:EBITDA (Average)

8 Years
5 Years
3 Years

15.64
16.23
16.93

Earnings Forecasts:

Description 2024 2025 2026 2027
Adj EPS 2.17
P/E Ratio 35.65
Revenue 1529
EBITDA 162
Net Income 111
ROA 9.3
P/B Ratio 4.45
ROE 13.29
FCFF 1.99
FCFF Yield 0.05

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Dec 24 Dec 23 Var% Sep 24 Sep 23 Var% Jun 24 Jun 23 Var% Mar 24 Mar 23 Var%
Net Sales 403.25 394.63 2.18% 383.70 381.26 0.64% 385.64 369.10 4.48% 392.60 336.52 16.66%
Expenses 371.68 343.52 8.20% 340.63 351.50 -3.09% 337.03 344.30 -2.11% 336.46 321.39 4.69%
EBITDA 31.58 51.12 -38.22% 43.06 29.76 44.69% 48.61 24.80 96.01% 56.14 15.13 271.05%
EBIDTM 7.83% 12.95% 11.22% 7.81% 12.60% 6.72% 14.30% 4.50%
Other Income 4.87 3.66 33.06% 4.63 2.84 63.03% 3.07 2.08 47.60% 3.99 2.99 33.44%
Interest 1.27 2.04 -37.75% 1.05 0.45 133.33% 1.04 0.28 271.43% 0.73 0.56 30.36%
Depreciation 4.81 5.51 -12.70% 3.79 4.81 -21.21% 3.59 4.89 -26.58% 6.69 4.61 45.12%
PBT 30.38 47.22 -35.66% 42.86 27.33 56.82% 47.05 21.71 116.72% 52.71 12.94 307.34%
Tax 7.69 12.02 -36.02% 10.93 7.41 47.50% 12.00 5.86 104.78% 12.75 2.67 377.53%
PAT 22.69 35.20 -35.54% 31.93 19.92 60.29% 35.05 15.85 121.14% 39.96 10.28 288.72%
PATM 5.63% 8.92% 8.32% 5.23% 9.09% 4.29% 10.18% 3.05%
EPS 0.41 0.64 -35.94% 0.58 0.36 61.11% 0.64 0.29 120.69% 0.73 0.19 284.21%

Description Dec 24 Dec 23 Var% Sep 24 Sep 23 Var% Jun 24 Jun 23 Var% Mar 24 Mar 23 Var%
Net Sales 452.78 444.55 1.85% 437.73 421.77 3.78% 455.22 401.04 13.51% 423.07 363.69 16.33%
Expenses 416.64 393.99 5.75% 393.66 388.18 1.41% 403.60 374.95 7.64% 374.69 348.13 7.63%
EBITDA 36.14 50.57 -28.53% 44.07 33.59 31.20% 51.62 26.09 97.85% 48.38 15.56 210.93%
EBIDTM 7.98% 11.37% 10.07% 7.96% 11.34% 6.51% 11.44% 4.28%
Other Income 5.34 4.07 31.20% 4.99 3.24 54.01% 3.43 2.42 41.74% 4.24 3.12 35.90%
Interest 1.34 2.17 -38.25% 1.18 0.46 156.52% 1.15 0.28 310.71% 0.80 0.56 42.86%
Depreciation 4.93 8.45 -41.66% 1.86 7.69 -75.81% 5.73 7.71 -25.68% 9.62 6.98 37.82%
PBT 35.20 44.02 -20.04% 46.02 28.68 60.46% 48.17 20.51 134.86% 42.20 11.14 278.82%
Tax 8.52 12.03 -29.18% 11.17 7.43 50.34% 12.00 5.88 104.08% 13.46 2.90 364.14%
PAT 26.69 31.99 -16.57% 34.85 21.26 63.92% 36.17 14.63 147.23% 28.74 8.24 248.79%
PATM 5.89% 7.20% 7.96% 5.04% 7.95% 3.65% 6.79% 2.27%
EPS 0.49 0.63 -22.22% 0.64 0.42 52.38% 0.71 0.29 144.83% 0.55 0.16 243.75%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone

Description TTM Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Net Sales 1,565.19 1,537.59 1,338.88 1,449.27 1,112.42 791.99 717.24 560.83 547.51 452.46 370.26 Net Sales Growth 5.65% 14.84% -7.62% 30.28% 40.46% 10.42% 27.89% 2.43% 21.01% 22.20% Cost Of Goods Sold 956.78 904.73 847.50 921.58 691.36 487.87 448.98 335.30 328.24 273.04 223.63 Gross Profit 608.41 632.87 491.39 527.68 421.06 304.13 268.26 225.52 219.27 179.42 146.64 GP Margin 38.87% 41.16% 36.70% 36.41% 37.85% 38.40% 37.40% 40.21% 40.05% 39.65% 39.60% Total Expenditure 1,385.80 1,375.77 1,261.61 1,320.13 1,000.05 727.52 652.22 500.56 487.02 388.26 323.68 Power & Fuel Cost - 34.09 23.78 18.93 13.00 12.56 13.18 11.08 9.84 7.64 7.41 % Of Sales - 2.22% 1.78% 1.31% 1.17% 1.59% 1.84% 1.98% 1.80% 1.69% 2.00% Employee Cost - 160.28 146.19 150.00 123.20 98.07 84.74 68.22 60.79 51.67 43.52 % Of Sales - 10.42% 10.92% 10.35% 11.07% 12.38% 11.81% 12.16% 11.10% 11.42% 11.75% Manufacturing Exp. - 95.50 91.66 98.96 66.82 48.90 31.27 16.21 15.05 13.33 12.63 % Of Sales - 6.21% 6.85% 6.83% 6.01% 6.17% 4.36% 2.89% 2.75% 2.95% 3.41% General & Admin Exp. - 58.56 50.41 35.93 29.69 31.93 31.21 24.35 21.53 15.34 13.77 % Of Sales - 3.81% 3.77% 2.48% 2.67% 4.03% 4.35% 4.34% 3.93% 3.39% 3.72% Selling & Distn. Exp. - 99.15 84.91 44.90 44.09 35.75 31.72 29.13 29.04 19.87 16.06 % Of Sales - 6.45% 6.34% 3.10% 3.96% 4.51% 4.42% 5.19% 5.30% 4.39% 4.34% Miscellaneous Exp. - 23.47 17.16 49.84 31.89 12.45 11.11 16.26 22.53 7.38 16.06 % Of Sales - 1.53% 1.28% 3.44% 2.87% 1.57% 1.55% 2.90% 4.11% 1.63% 1.80% EBITDA 179.39 161.82 77.27 129.14 112.37 64.47 65.02 60.27 60.49 64.20 46.58 EBITDA Margin 11.46% 10.52% 5.77% 8.91% 10.10% 8.14% 9.07% 10.75% 11.05% 14.19% 12.58% Other Income 16.56 12.57 5.76 20.03 11.77 9.42 3.67 3.54 3.72 1.17 1.36 Interest 4.09 3.51 1.98 2.43 1.79 1.97 2.07 4.29 7.47 10.41 8.63 Depreciation 18.88 21.90 18.01 21.19 28.11 34.43 38.01 33.40 33.56 34.92 38.59 PBT 173.00 148.98 63.04 125.54 94.25 37.48 28.61 26.12 23.17 20.04 0.72 Tax 43.37 38.04 16.80 24.48 0.00 5.15 0.00 0.00 0.00 -0.14 0.14 Tax Rate 25.07% 25.53% 26.65% 19.50% 0.00% 13.74% 0.00% 0.00% 0.00% -0.90% 19.44% PAT 129.63 110.94 46.24 101.06 94.25 32.33 28.61 26.12 23.17 15.78 0.58 PAT before Minority Interest 129.63 110.94 46.24 101.06 94.25 32.33 28.61 26.12 23.17 15.78 0.58 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 8.28% 7.22% 3.45% 6.97% 8.47% 4.08% 3.99% 4.66% 4.23% 3.49% 0.16% PAT Growth 59.54% 139.92% -54.25% 7.23% 191.52% 13.00% 9.53% 12.73% 46.83% 2,620.69% EPS 2.37 2.02 0.84 1.84 1.72 0.59 0.52 0.48 0.42 0.29 0.01

Description TTM Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Net Sales 1,768.80 1,690.43 1,417.53 1,546.83 1,188.06 853.07 768.54 606.51 595.47 485.08 400.64 Net Sales Growth 8.45% 19.25% -8.36% 30.20% 39.27% 11.00% 26.72% 1.85% 22.76% 21.08% Cost Of Goods Sold 1,100.08 1,016.87 900.22 980.35 735.29 524.19 479.12 361.28 358.35 293.33 238.62 Gross Profit 668.72 673.56 517.31 566.47 452.77 328.87 289.42 245.23 237.12 191.76 162.02 GP Margin 37.81% 39.85% 36.49% 36.62% 38.11% 38.55% 37.66% 40.43% 39.82% 39.53% 40.44% Total Expenditure 1,588.59 1,531.81 1,338.00 1,410.15 1,069.54 784.55 701.02 541.78 534.09 423.52 352.41 Power & Fuel Cost - 34.09 23.78 18.93 13.00 12.56 13.18 11.08 9.84 7.64 7.41 % Of Sales - 2.02% 1.68% 1.22% 1.09% 1.47% 1.71% 1.83% 1.65% 1.57% 1.85% Employee Cost - 181.47 154.68 164.25 135.59 109.91 95.36 76.53 69.69 58.29 48.79 % Of Sales - 10.74% 10.91% 10.62% 11.41% 12.88% 12.41% 12.62% 11.70% 12.02% 12.18% Manufacturing Exp. - 95.75 91.70 98.99 67.21 48.92 31.28 16.21 22.36 13.33 12.68 % Of Sales - 5.66% 6.47% 6.40% 5.66% 5.73% 4.07% 2.67% 3.76% 2.75% 3.16% General & Admin Exp. - 66.63 55.44 42.38 34.71 36.47 36.14 28.52 18.11 18.14 15.89 % Of Sales - 3.94% 3.91% 2.74% 2.92% 4.28% 4.70% 4.70% 3.04% 3.74% 3.97% Selling & Distn. Exp. - 109.98 93.01 53.58 49.66 40.11 32.73 30.04 25.79 23.45 21.40 % Of Sales - 6.51% 6.56% 3.46% 4.18% 4.70% 4.26% 4.95% 4.33% 4.83% 5.34% Miscellaneous Exp. - 27.02 19.17 51.67 34.08 12.39 13.20 18.11 29.95 9.35 21.40 % Of Sales - 1.60% 1.35% 3.34% 2.87% 1.45% 1.72% 2.99% 5.03% 1.93% 1.90% EBITDA 180.21 158.62 79.53 136.68 118.52 68.52 67.52 64.73 61.38 61.56 48.23 EBITDA Margin 10.19% 9.38% 5.61% 8.84% 9.98% 8.03% 8.79% 10.67% 10.31% 12.69% 12.04% Other Income 18.00 13.97 6.13 20.10 12.07 9.48 3.67 3.72 3.72 1.20 1.37 Interest 4.47 3.71 1.98 2.43 1.79 1.98 2.11 4.36 7.56 10.50 8.66 Depreciation 22.14 33.47 27.93 27.64 30.28 36.91 39.90 34.32 33.90 35.20 38.67 PBT 171.59 135.42 55.76 126.70 98.51 39.11 29.18 29.77 23.63 17.06 2.28 Tax 45.15 38.80 17.08 25.02 1.42 5.53 0.34 0.00 0.00 -0.13 0.14 Tax Rate 26.31% 28.65% 30.63% 19.75% 1.44% 14.14% 1.17% 0.00% 0.00% -1.03% 6.14% PAT 126.45 96.16 38.68 101.68 97.09 33.58 28.85 29.59 23.63 12.80 2.14 PAT before Minority Interest 126.45 96.62 38.68 101.68 97.09 33.58 28.84 29.77 23.63 12.80 2.14 Minority Interest 0.00 -0.46 0.00 0.00 0.00 0.00 0.01 -0.18 0.00 0.00 0.00 PAT Margin 7.15% 5.69% 2.73% 6.57% 8.17% 3.94% 3.75% 4.88% 3.97% 2.64% 0.53% PAT Growth 66.12% 148.60% -61.96% 4.73% 189.13% 16.40% -2.50% 25.22% 84.61% 498.13% EPS 2.31 1.75 0.71 1.86 1.77 0.61 0.53 0.54 0.43 0.23 0.04

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Shareholder's Funds 889.02 780.11 598.17 444.97 307.25 277.46 250.56 224.34 328.85 313.08 Share Capital 102.23 102.23 95.56 89.96 89.96 89.96 89.96 89.96 209.61 209.61 Total Reserves 786.80 677.89 476.36 311.26 217.29 187.50 160.60 134.38 119.24 103.47 Non-Current Liabilities 37.65 34.45 32.41 26.89 25.36 21.11 17.87 15.28 55.22 72.69 Secured Loans 3.36 0.93 1.32 0.83 0.92 1.79 2.70 0.94 42.74 62.22 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 31.60 28.87 26.64 24.01 22.38 17.85 13.45 12.69 10.71 8.71 Current Liabilities 352.63 290.98 402.69 375.63 329.38 320.82 322.21 308.19 150.78 114.44 Trade Payables 267.43 213.10 217.32 192.33 158.38 157.08 164.89 116.20 107.48 78.55 Other Current Liabilities 38.66 39.79 159.63 163.93 157.39 153.61 156.05 190.70 39.14 32.82 Short Term Borrowings 23.49 23.18 16.13 15.32 11.36 8.99 0.00 0.00 0.00 2.23 Short Term Provisions 23.05 14.91 9.61 4.05 2.25 1.14 1.26 1.29 4.16 0.84 Total Liabilities 1,279.30 1,105.54 1,033.27 847.49 661.99 619.39 590.64 547.81 534.85 500.21 Net Block 216.54 170.82 156.11 144.02 134.84 152.59 182.10 191.29 216.36 243.93 Gross Block 477.36 512.07 479.46 516.17 641.54 777.14 890.30 922.26 914.18 907.16 Accumulated Depreciation 260.83 341.25 323.35 372.14 506.70 624.55 708.20 730.96 697.82 663.23 Non Current Assets 436.40 374.69 356.50 354.71 313.73 336.06 363.54 369.25 387.98 395.80 Capital Work in Progress 24.45 17.01 14.15 1.96 0.00 0.00 0.00 0.00 0.00 0.00 Non Current Investment 126.18 117.84 117.79 118.78 118.78 117.69 117.69 117.69 117.69 117.94 Long Term Loans & Adv. 68.99 68.74 68.17 89.67 59.83 65.49 63.47 59.41 53.92 33.93 Other Non Current Assets 0.24 0.28 0.28 0.27 0.28 0.28 0.27 0.85 0.00 0.00 Current Assets 842.91 730.85 676.76 492.79 348.26 283.33 227.11 178.56 146.88 104.41 Current Investments 0.00 0.00 0.00 0.00 0.00 0.02 0.22 0.00 0.00 0.00 Inventories 220.15 211.35 258.25 169.61 132.47 90.84 73.94 62.50 40.82 35.36 Sundry Debtors 316.89 255.47 221.87 155.52 121.41 121.96 110.22 83.10 80.35 48.45 Cash & Bank 50.48 55.90 45.55 66.98 38.03 31.98 5.70 6.75 3.63 8.60 Other Current Assets 255.39 4.97 5.07 9.80 56.35 38.52 37.02 26.22 22.08 12.00 Short Term Loans & Adv. 239.12 203.16 146.02 90.88 50.45 30.80 31.53 21.67 16.27 8.89 Net Current Assets 490.27 439.87 274.07 117.16 18.88 -37.49 -95.10 -129.63 -3.91 -10.03 Total Assets 1,279.31 1,105.54 1,033.26 847.50 661.99 619.39 590.65 547.81 534.86 500.21

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Shareholder's Funds 847.23 752.91 578.56 424.75 284.06 253.09 225.94 196.26 300.28 287.48 Share Capital 102.23 102.23 95.56 89.96 89.96 89.96 89.96 89.96 209.61 209.61 Total Reserves 745.00 650.68 456.75 291.04 194.10 163.13 135.98 106.30 90.67 77.87 Non-Current Liabilities 43.93 36.88 35.50 30.06 28.42 23.38 20.20 17.80 57.47 74.00 Secured Loans 3.36 0.93 1.32 0.83 0.92 1.83 2.95 1.38 43.41 62.27 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 33.82 29.74 28.24 25.39 23.82 19.01 14.42 13.59 11.34 9.22 Current Liabilities 402.04 321.16 456.46 403.80 351.44 339.17 340.12 324.86 166.56 127.92 Trade Payables 295.03 226.88 258.12 208.85 172.30 168.15 174.88 124.88 115.33 84.96 Other Current Liabilities 58.51 54.86 169.97 174.38 165.06 160.64 163.90 198.65 47.04 39.87 Short Term Borrowings 23.49 23.18 16.13 15.32 11.36 8.99 0.00 0.00 0.00 2.23 Short Term Provisions 25.02 16.24 12.24 5.25 2.72 1.39 1.33 1.33 4.19 0.86 Total Liabilities 1,293.20 1,110.49 1,070.06 858.15 663.46 615.18 585.81 538.29 523.68 489.00 Net Block 307.35 266.97 251.80 224.52 216.37 236.21 264.29 271.80 296.72 322.48 Gross Block 620.63 656.24 613.25 628.32 752.55 887.76 997.60 1,026.96 1,018.43 1,009.35 Accumulated Depreciation 313.28 389.27 361.45 403.79 536.18 651.55 733.31 755.15 721.72 686.87 Non Current Assets 404.16 354.33 335.75 331.36 291.29 315.71 342.37 346.34 366.53 374.42 Capital Work in Progress 24.45 17.01 14.15 1.96 0.00 0.00 0.00 0.00 0.00 0.00 Non Current Investment 1.30 0.00 0.00 1.08 1.08 0.00 0.00 0.00 0.00 0.00 Long Term Loans & Adv. 70.82 70.07 69.53 103.52 73.55 79.22 77.81 73.69 69.82 51.94 Other Non Current Assets 0.24 0.28 0.28 0.27 0.28 0.28 0.27 0.85 0.00 0.00 Current Assets 889.04 756.16 734.30 526.79 372.18 299.47 243.44 191.95 157.15 114.58 Current Investments 0.00 0.00 0.00 0.00 0.00 0.02 0.22 0.00 0.00 0.00 Inventories 248.59 228.89 275.85 175.33 138.48 94.20 76.89 64.66 42.14 37.11 Sundry Debtors 324.94 263.25 250.64 181.98 137.68 133.75 121.85 92.95 87.94 56.14 Cash & Bank 52.12 56.31 45.97 67.89 38.88 32.21 5.95 7.59 4.36 8.85 Other Current Assets 263.40 7.15 5.29 10.01 57.14 39.29 38.54 26.74 22.71 12.48 Short Term Loans & Adv. 246.96 200.58 156.54 91.58 51.16 31.43 32.92 22.03 16.77 9.34 Net Current Assets 487.00 435.00 277.84 122.99 20.73 -39.70 -96.68 -132.92 -9.41 -13.34 Total Assets 1,293.20 1,110.49 1,070.05 858.15 663.47 615.18 585.81 538.29 523.68 489.00

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Cash From Operating Activity 77.36 -102.12 -68.87 49.31 10.86 14.58 61.25 49.24 50.01 50.74 PBT 148.98 63.04 125.54 94.25 37.48 28.61 26.12 22.55 20.04 0.72 Adjustment 22.70 18.01 13.02 29.63 34.23 38.36 37.86 40.92 45.32 47.22 Changes in Working Capital -56.96 -166.90 -183.04 -74.56 -55.33 -52.40 -2.72 -14.23 -11.09 2.94 Cash after chg. in Working capital 114.72 -85.84 -44.47 49.31 16.38 14.58 61.25 49.24 54.27 50.88 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -37.36 -16.27 -24.39 0.00 -5.52 0.00 0.00 0.00 0.14 -0.14 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -4.40 0.00 Cash From Investing Activity -83.60 -36.20 -22.64 -69.09 -12.08 -10.34 -24.28 -14.67 -27.08 -30.22 Net Fixed Assets 27.27 -35.47 24.52 123.41 135.60 113.16 31.96 -8.08 -7.02 -4.73 Net Investments -8.34 -0.05 0.99 0.00 -1.07 0.20 -0.22 0.00 0.25 0.00 Others -102.53 -0.68 -48.15 -192.50 -146.61 -123.70 -56.02 -6.59 -20.31 -25.49 Cash from Financing Activity 0.28 144.20 66.41 47.46 4.65 -0.35 -37.67 -31.29 -27.89 -19.99 Net Cash Inflow / Outflow -5.96 5.88 -25.09 27.68 3.43 3.89 -0.69 3.29 -4.97 0.53 Opening Cash & Equivalents 21.26 15.38 40.47 12.79 9.36 5.47 6.16 2.87 8.60 8.07 Closing Cash & Equivalent 15.30 21.26 15.38 40.47 12.79 9.36 5.47 6.16 3.63 8.60

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Cash From Operating Activity 73.37 -91.17 -60.24 50.83 11.02 17.37 63.41 40.73 50.07 50.70 PBT 135.42 55.76 126.70 98.51 39.11 29.18 29.77 23.04 17.06 2.28 Adjustment 34.20 27.90 19.46 31.96 36.63 40.32 38.64 41.40 45.69 47.32 Changes in Working Capital -58.12 -158.28 -181.47 -78.18 -58.84 -51.78 -5.00 -23.72 -8.41 1.23 Cash after chg. in Working capital 111.49 -74.62 -35.31 52.29 16.89 17.71 63.41 40.73 54.34 50.83 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -38.12 -16.55 -24.93 -1.46 -5.88 -0.34 0.00 0.00 0.13 -0.13 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -4.40 0.00 Cash From Investing Activity -83.30 -46.51 -31.68 -70.35 -12.46 -13.05 -26.93 -13.60 -27.30 -31.65 Net Fixed Assets 27.27 -35.47 24.52 123.41 135.60 113.16 31.96 -8.08 -7.02 -4.73 Net Investments -8.34 -0.05 0.99 0.00 -1.07 0.20 -0.22 0.00 0.25 0.00 Others -102.23 -10.99 -57.19 -193.76 -146.99 -126.41 -58.67 -5.52 -20.53 -26.92 Cash from Financing Activity 5.20 143.54 66.33 47.27 5.49 -0.44 -37.77 -23.72 -27.26 -19.31 Net Cash Inflow / Outflow -4.72 5.86 -25.58 27.75 4.04 3.88 -1.29 3.40 -4.49 -0.26 Opening Cash & Equivalents 21.67 15.80 41.39 13.64 9.60 5.72 7.00 3.60 8.85 9.11 Closing Cash & Equivalent 16.95 21.67 15.80 41.39 13.64 9.60 5.72 7.00 4.36 8.85

Financial Ratios

Consolidated /

Standalone

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Book Value (Rs.) 17.39 15.26 11.97 8.92 6.83 6.17 5.57 4.99 4.65 4.30 ROA 9.30% 4.32% 10.75% 12.49% 5.05% 4.73% 4.59% 4.28% 3.05% 0.12% ROE 13.29% 6.84% 20.77% 26.61% 11.06% 10.84% 11.00% 10.69% 7.84% 0.29% ROCE 17.71% 9.15% 23.73% 24.54% 10.82% 7.74% 9.26% 9.17% 6.60% 2.32% Fixed Asset Turnover 3.11 2.70 2.91 1.92 1.12 0.86 0.62 0.60 0.51 0.42 Receivable days 67.93 65.07 47.52 45.43 56.08 59.08 62.91 54.48 50.93 42.76 Inventory Days 51.22 64.01 53.88 49.56 51.46 41.93 44.40 34.44 30.13 32.97 Payable days 96.93 92.69 81.12 92.58 79.07 88.97 104.24 84.35 83.75 77.64 Cash Conversion Cycle 22.22 36.39 20.28 2.41 28.47 12.04 3.07 4.58 -2.69 -1.90 Total Debt/Equity 0.03 0.03 0.03 0.04 0.04 0.47 0.53 0.22 0.20 0.26 Interest Cover 43.45 32.83 52.75 53.71 20.05 14.82 7.08 4.10 2.50 1.08

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Book Value (Rs.) 16.58 14.73 11.56 8.47 6.32 5.63 5.02 4.36 4.02 3.73 ROA 8.04% 3.55% 10.55% 12.76% 5.25% 4.80% 5.30% 4.45% 2.53% 0.44% ROE 12.08% 5.93% 21.79% 29.20% 12.50% 12.04% 14.10% 12.54% 7.35% 1.24% ROCE 16.82% 8.40% 24.86% 27.13% 12.05% 10.01% 14.05% 10.18% 6.29% 2.90% Fixed Asset Turnover 2.65 2.23 2.49 1.72 1.04 0.82 0.60 0.58 0.49 0.41 Receivable days 63.50 66.16 51.04 49.10 58.07 60.70 64.63 55.44 53.22 44.17 Inventory Days 51.55 64.98 53.23 48.20 49.78 40.63 42.59 32.73 29.27 31.48 Payable days 93.67 98.32 86.93 94.60 79.06 88.85 103.38 82.97 83.88 76.01 Cash Conversion Cycle 21.38 32.82 17.35 2.71 28.78 12.48 3.85 5.20 -1.39 -0.36 Total Debt/Equity 0.03 0.03 0.03 0.04 0.05 0.52 0.06 0.25 0.22 0.28 Interest Cover 37.50 29.15 53.22 56.09 20.71 14.83 7.83 4.13 2.21 1.26

Top Investors:

pinfold overseas limited

morepen laboratories limited

Annual Reports:

News Update:

Morepen Laboratories to launch new drug for Fatty Liver
29th Apr 2025, 12:50 PM

The company has received clearance from Subject Expert Committee of CDSCO to conduct Bioequivalence studies for Resmetirom 60 mg, 80 mg and 100 mg tablets
Read More
Morepen Laboratories gets nod to incorporate wholly owned subsidiary in Dubai
29th Apr 2025, 10:09 AM

The Finance Committee of the Board of Directors of the Company, at its meeting held on April 28, 2025 has approved the same
Read More
Morepen Laboratories secures Loratadine approval for export to China
1st Apr 2025, 09:50 AM

This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
Read More
Morepen Laboratories incorporates step-down subsidiary
20th Mar 2025, 18:02 PM

Quick Med is a subsidiary of Dr. Morepen
Read More
Morepen Laboratories to transfer Medical Devices Business
19th Mar 2025, 14:46 PM

The Medical Devices Business will be transferred to Morepen Medtech
Read More
Morepen Laboratories launches Empamore
18th Mar 2025, 09:29 AM

Morepen manufactures Empagliflozin in its USFDA-approved facilities and already has European DMF
Read More
Morepen Laboratories’ arm gets nod to form new subsidiary company
19th Feb 2025, 14:51 PM

The proposed new company will operate in the pharmaceutical sector, specializing in the 'Online Retail Pharmacy' business
Read More
Morepen Laboratories - Quarterly Results
6th Feb 2025, 14:11 PM

Read More

Morepen Laboratories Ltd.

Pharmaceuticals & Drugs - API

BSE: 500288 | NSE: MOREPENLAB

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update:

Morepen Laboratories Ltd.

Pharmaceuticals & Drugs - API

BSE: 500288 | NSE: MOREPENLAB

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update: